TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31241381

Group type: EXPERIMENTAL
Intervention: Self-reported xerostomia assessment using EORTC QLQ-H&N35 questionnaire
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Physician-rated xerostomia assessment using DAHANCA toxicity scale
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Multi-variable analysis including doses to the oral cavity, tobacco status, and use of xerogenic medication
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Dose-volume histogram (DVH) analysis and principal component analysis (PCA)
Number of subjects: 109
Study: 28399129

Group type: EXPERIMENTAL
Intervention: Point-of-care anxiety and depression screening prompted by an automated electronic template comprising five questions (including a two-item Patient Health Questionnaire-2 for depression and a two-item Generalized Anxiety Disorder-2 questionnaire for anxiety).
Number of subjects: 704

Group type: COMPARATOR
Intervention: Control group prompted GPs to ask only the pain intensity question.
Number of subjects: 704
Study: 24989855

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) 1.25 mg administered intra-operatively, and at 4 and 8 weeks after surgery
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no IVB)
Number of subjects: 40
Study: 22882281

Group type: EXPERIMENTAL
Intervention: Exenatide (supratherapeutic concentrations)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moxifloxacin
Number of subjects: 0
Study: 21330581

Group type: EXPERIMENTAL
Intervention: Social marketing region (rebates, messages, and promotion)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Control region (no incentives)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Social marketing region
Number of subjects: 391
Study: 19675392

Group type: EXPERIMENTAL
Intervention: Progressive muscular relaxation (PMR) training plus exercise training and lifestyle education (relaxation group; n=55)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Usual care (exercise training and lifestyle education; control group; n=55)
Number of subjects: 110
Study: 17761570

Group type: EXPERIMENTAL
Intervention: Identifying patients' smoking status
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Counseling about smoking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smoking cessation medication use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Counseling for smoking
Number of subjects: 0
Study: 15475437

Group type: EXPERIMENTAL
Intervention: Budesonide (Pulmicort Turbuhaler) 800 microg twice daily inhalation for 6 months
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 15973519

Group type: EXPERIMENTAL
Intervention: Gln‐PN (0.5 g/kg per day; n=15)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control‐PN (standard Gln‐free PN; n=14)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Gln‐PN
Number of subjects: 29
Study: 10442372

Group type: COMPARATOR
Intervention: Oral tamoxifen 20 mg/day for 2 years (group A)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Oral UFT 400 mg/day plus tamoxifen 20 mg/day (group B)
Number of subjects: 444
Study: 8755848

Group type: EXPERIMENTAL
Intervention: Pheochromocytoma patients before surgery
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Pheochromocytoma patients after pharmacological treatment
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Pheochromocytoma patients after excision of the tumor
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Pheochromocytoma patients before any treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (25 healthy volunteers)
Number of subjects: 28
Study: 1914554

Group type: EXPERIMENTAL
Intervention: Transdermal clonidine delivery system (TTS-1, 0.1 mg/day)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 6351231

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol (50 micrograms/puff) one puff per nostril X 4 (daily dose 400 micrograms)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol two puffs per nostril X 2 (daily dose 400 micrograms)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo one puff per nostril X 4
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo two puffs per nostril X 2
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both active drugs
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: NPEF and use of antihistamine tablets
Number of subjects: 70
Study: 29776873

Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Reflexology + PMR
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 29326407

Group type: EXPERIMENTAL
Intervention: Smart Program for Patients Who Underwent Percutaneous Coronary Intervention (SP-PCI)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Usual care from primary health care providers and brief health education
Number of subjects: 48
Study: 26606004

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 39

Group type: COMPARATOR
Intervention: Relaxation therapy
Number of subjects: 39
Study: 24417602

Group type: EXPERIMENTAL
Intervention: Online positive psychology intervention (OPPI) cultivating optimism
Number of subjects: 466

Group type: COMPARATOR
Intervention: Control condition writing about daily activities
Number of subjects: 466
Study: 22958476

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) (Flebogamma®, 2 g/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (previous therapy)
Number of subjects: 20
Study: 19900238

Group type: EXPERIMENTAL
Intervention: Diabetes-specific Expert Patient Programme (EPP) (n = 162)
Number of subjects: 317

Group type: COMPARATOR
Intervention: Individual one-off appointments with a dietitian (Control group) (n = 155)
Number of subjects: 317
Study: 17410097

Group type: EXPERIMENTAL
Intervention: sirolimus/mycophenolate mofetil/methylprednisolone (SRL)
Number of subjects: 24

Group type: COMPARATOR
Intervention: cyclosporine with either mycophenolate mofetil or methylprednisolone (CsA)
Number of subjects: 24
Study: 15675636

Group type: EXPERIMENTAL
Intervention: Lifestyle modification program
Number of subjects: 279

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 279
Study: 11176549

Group type: EXPERIMENTAL
Intervention: Usual medical care plus clinical pharmacist interventions
Number of subjects: 1054

Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 1054
Study: 9682118

Group type: EXPERIMENTAL
Intervention: Intracameral injection of unpreserved lidocaine (0.5 cc of a 1% unpreserved solution)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Balanced salt solution (control)
Number of subjects: 100
Study: 8018617

Group type: EXPERIMENTAL
Intervention: Intramyometrial vasopressin (20 units diluted to 20 ml in normal saline)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (20 ml normal saline)
Number of subjects: 20
Study: 29976228

Group type: EXPERIMENTAL
Intervention: Intermittent screening and treatment with artemether-lumefantrine (ISTp-AL)
Number of subjects: 459
Study: 28477959

Group type: EXPERIMENTAL
Intervention: Protocol B (novel contrast medium formula)
Number of subjects: 120
Study: 26221889

Group type: EXPERIMENTAL
Intervention: Embolization + mecobalamin treatment
Number of subjects: 56

Group type: COMPARATOR
Intervention: Embolization treatment
Number of subjects: 56
Study: 24215148

Group type: EXPERIMENTAL
Intervention: Compassion focused therapy (CFT) plus treatment as usual (TAU)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Compassion focused therapy (CFT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 40
Study: 21136070

Group type: EXPERIMENTAL
Intervention: Rectal acetaminophen (30 mg/kg)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Peritonsillar bupivacaine infiltration (1 mg/kg)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Parents' and nurses' satisfaction regarding patient analgesia
Number of subjects: 110
Study: 18523108

Group type: EXPERIMENTAL
Intervention: Paraprofessional home visitation program (HVP) with four visits every two weeks focusing on injury prevention practices, home inspection, and supply of safety devices.
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Paraprofessional home visitation program (HVP)
Number of subjects: 400
Study: 16740758

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 643

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 643
Study: 12915284

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral training program for parents
Number of subjects: 242

Group type: COMPARATOR
Intervention: Information-centered standard program
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 242
Study: 10693094

Group type: EXPERIMENTAL
Intervention: Ibuprofen (10 mg/kg loading dose followed by 5 mg/kg every 12 hours)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (conventional treatment)
Number of subjects: 18
Study: 9339154

Group type: EXPERIMENTAL
Intervention: Supinator garment
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pronator garment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Garments with no torsional force
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All garments
Number of subjects: 10
Study: 8157041

Group type: EXPERIMENTAL
Intervention: Probenecid
Number of subjects: 0
Study: 3818510

Group type: EXPERIMENTAL
Intervention: MDI plus Aerochamber
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Jet nebulizer
Number of subjects: 15
Study: 29721510

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation group (≥42 patients)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard pharmacotherapy alone (≥21 patients)
Number of subjects: 63
Study: 27918466

Group type: EXPERIMENTAL
Intervention: Dog safety website
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control transportation safety website
Number of subjects: 69
Study: 24562087

Group type: EXPERIMENTAL
Intervention: DBT+DBT PE
Number of subjects: 26

Group type: COMPARATOR
Intervention: DBT
Number of subjects: 26
Study: 22593114

Group type: EXPERIMENTAL
Intervention: 50-Hz rTMS
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 26
Study: 20940522

Group type: EXPERIMENTAL
Intervention: Naftopidil 50mg once daily (Naf group)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Tamsulosin 0.2mg once daily (Tam group)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 68

Group type: COMPARATOR
Intervention: Naf vs Tam
Number of subjects: 68
Study: 18165400

Group type: EXPERIMENTAL
Intervention: Titrated oral misoprostol
Number of subjects: 207

Group type: COMPARATOR
Intervention: Vaginal misoprostol
Number of subjects: 207
Study: 15823909

Group type: EXPERIMENTAL
Intervention: UVB treatment guided by skin reflectance measurements
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional UVB regimen with fixed dosage increments
Number of subjects: 20
Study: 11978674

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Sulfonylurea, Metformin, or Insulin
Number of subjects: 6000
Study: 10071153

Group type: EXPERIMENTAL
Intervention: Stage 3 ROP
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Stage 2 and 3 ROP
Number of subjects: 144

Group type: COMPARATOR
Intervention: Healthy preterm infants (Control)
Number of subjects: 144
Study: 7574132

Group type: EXPERIMENTAL
Intervention: Nebulized dexamethasone (1.5 mg/kg)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Oral prednisone (2 mg/kg)
Number of subjects: 111
Study: 2150736

Group type: EXPERIMENTAL
Intervention: Aspirin (300-1500 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin (160 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of aspirin with streptokinase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin in healthy doctors (primary prevention trials)
Number of subjects: 0
Study: 6771599

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 31880796

Group type: EXPERIMENTAL
Intervention: Lemborexant 5 mg
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg
Number of subjects: 1006
Study: 29525822

Group type: EXPERIMENTAL
Intervention: Ticagrelor (180-mg loading dose, 90 mg twice daily thereafter)
Number of subjects: 3799

Group type: COMPARATOR
Intervention: Clopidogrel (300-600 mg loading dose, 75 mg daily thereafter)
Number of subjects: 3799

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 3799

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 3799
Study: 27093052

Group type: EXPERIMENTAL
Intervention: Joint reminiscence groups (weekly for twelve weeks; monthly maintenance sessions for further seven months)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 488
Study: 24091061

Group type: EXPERIMENTAL
Intervention: Mailed intervention providing instructions for taste exposure (14 daily tastes of a disliked vegetable with a sticker reward)
Number of subjects: 472

Group type: COMPARATOR
Intervention: No treatment control condition
Number of subjects: 472
Study: 21822913

Group type: EXPERIMENTAL
Intervention: Casopitant 90 mg IV added to ondansetron 8 mg bid oral and dexamethasone 8 mg IV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo added to ondansetron 8 mg bid oral and dexamethasone 8 mg IV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Casopitant 90 mg IV
Number of subjects: 0
Study: 20934965

Group type: EXPERIMENTAL
Intervention: Propofol (TIVA)
Number of subjects: 84
Study: 18182866

Group type: EXPERIMENTAL
Intervention: Cognitive behavior program applied twice a week for 50 minutes per session over six weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 16235461

Group type: EXPERIMENTAL
Intervention: True ES (electrical stimulation) of ST36 and ST38 acupoints with nitroglycerin infusion
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sham ES of ST36 and ST38 acupoints with nitroglycerin infusion
Number of subjects: 51
Study: 12198061

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.1% 8 mL plus 75 microg of clonidine (Group 1)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.2% 8 mL plus 75 microg of clonidine (Group 3)
Number of subjects: 66

Group type: COMPARATOR
Intervention: ropivacaine 0.2% 8 mL plus 0.5 mL of NaCl 0.9% (Group 2)
Number of subjects: 66
Study: 10450266

Group type: EXPERIMENTAL
Intervention: Moderate dose of alcohol before the second speech
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo alcoholic drink before both speeches
Number of subjects: 40
Study: 8666102

Group type: EXPERIMENTAL
Intervention: ZIOS
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: sRaw
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ptc,O2
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Rint
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: FEV1
Number of subjects: 21

Group type: COMPARATOR
Intervention: Beta 2-agonist
Number of subjects: 21
Study: 2135708

Group type: EXPERIMENTAL
Intervention: Propentofylline (3 x 300 mg)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo (3 x 1 tablet)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Propentofylline (EEG brain mapping)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo (EEG brain mapping)
Number of subjects: 190
Study: 7358206

Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Betamethasone phosphate/acetate
Number of subjects: 60
Study: 30290851

Group type: EXPERIMENTAL
Intervention: Information plus intervention group (receiving text messages with HIV prevention information and quiz questions with prize opportunities)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Information only control group (receiving text messages with HIV prevention information)
Number of subjects: 200
Study: 27627654

Group type: EXPERIMENTAL
Intervention: AmBisome + SSG (10 mg/kg single dose AmBisome plus 10 days of SSG at 20 mg/kg/day)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: AmBisome + Miltefosine (10 mg/kg single dose AmBisome plus 10 days of miltefosine at 2.5 mg/kg/day)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Miltefosine alone (2.5 mg/kg/day for 28 days)
Number of subjects: 51
Study: 24619855

Group type: EXPERIMENTAL
Intervention: Sub-Tenon block (ST)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Intravenous fentanyl (F)
Number of subjects: 67
Study: 22119570

Group type: EXPERIMENTAL
Intervention: Postoperative doxycycline treatment
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Surgical stabilisation
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control stifles of unaffected dogs
Number of subjects: 13
Study: 19913346

Group type: EXPERIMENTAL
Intervention: ECC with device
Number of subjects: 93

Group type: COMPARATOR
Intervention: ECC without device
Number of subjects: 93
Study: 18274908

Group type: EXPERIMENTAL
Intervention: HBV video
Number of subjects: 328

Group type: COMPARATOR
Intervention: Smoking prevention video
Number of subjects: 328
Study: 16183787

Group type: EXPERIMENTAL
Intervention: Galactose-deficient IgG levels in serum and gingival crevicular fluid from periodontal disease patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gingival tissue from periodontal disease patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IgG secreted by B-cells in periodontal disease patients
Number of subjects: 0
Study: 12604870

Group type: EXPERIMENTAL
Intervention: Regular exercise (n=24)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Non-exercisers (n=17)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Regular exercise
Number of subjects: 41
Study: 10783345

Group type: EXPERIMENTAL
Intervention: recombinant follicle stimulating hormone (rFSH; follitropin alpha)
Number of subjects: 168

Group type: COMPARATOR
Intervention: highly purified urinary FSH (uFSH; urofollitropin HP)
Number of subjects: 168
Study: 8938163

Group type: EXPERIMENTAL
Intervention: IFN-alpha2a (6 million units starting dose, titrated for 12 months)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: IFN-alphaN1 (6 million units starting dose, titrated for 12 months)
Number of subjects: 234

Group type: COMPARATOR
Intervention: IFN-alpha2a
Number of subjects: 234

Group type: COMPARATOR
Intervention: IFN-alphaN1
Number of subjects: 234
Study: 1612300

Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: L-hyoscyamine
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 6428279

Group type: EXPERIMENTAL
Intervention: Ketotifen 1 mg p.o. q 12 h
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 30617102

Group type: EXPERIMENTAL
Intervention: e-assist: Colon Health
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care plus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 30131303

Group type: EXPERIMENTAL
Intervention: Class 3 compression stockings (Tubulcus; Laboratoires Innothera, Arcueil, France)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Class 2 compression stockings (Rudo, Nis, Serbia)
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Class 3 compression stockings
Number of subjects: 361

Group type: COMPARATOR
Intervention: Class 2 compression stockings
Number of subjects: 361
Study: 26530475

Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 27
Study: 25176015

Group type: EXPERIMENTAL
Intervention: LCZ696 (200 mg twice daily)
Number of subjects: 8442

Group type: COMPARATOR
Intervention: Enalapril (10 mg twice daily)
Number of subjects: 8442

Group type: EXPERIMENTAL
Intervention: LCZ696
Number of subjects: 8442

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 8442
Study: 22770372

Group type: EXPERIMENTAL
Intervention: Cisplatin (75mg/m2), pemetrexed (500mg/m2), and bevacizumab (15mg/kg) every 21 days for a maximum of 6 cycles.
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Cisplatin (75mg/m2), pemetrexed (500mg/m2), and bevacizumab (15mg/kg) every 21 days until progression or intolerance.
Number of subjects: 52

Group type: COMPARATOR
Intervention: Cisplatin and pemetrexed alone (historical control).
Number of subjects: 52
Study: 21098426

Group type: EXPERIMENTAL
Intervention: SmartDelay (electrogram-based algorithm)
Number of subjects: 1014

Group type: EXPERIMENTAL
Intervention: Echocardiography-optimized AV delay
Number of subjects: 1014

Group type: COMPARATOR
Intervention: Fixed AV delay (120 milliseconds)
Number of subjects: 1014

Group type: EXPERIMENTAL
Intervention: SmartDelay
Number of subjects: 1014

Group type: EXPERIMENTAL
Intervention: Echocardiography
Number of subjects: 1014
Study: 18500047

Group type: EXPERIMENTAL
Intervention: F+OG
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 2PC(vent)
Number of subjects: 8

Group type: COMPARATOR
Intervention: 1PC
Number of subjects: 8

Group type: COMPARATOR
Intervention: 2PC
Number of subjects: 8
Study: 15654172

Group type: EXPERIMENTAL
Intervention: Paroxetine 10 mg/day and psychotherapy for 8 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (28 patients)
Number of subjects: 34
Study: 12208593

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg q.d. (n=70)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Enalapril 10 mg b.i.d. (n=71)
Number of subjects: 141
Study: 10599365

Group type: EXPERIMENTAL
Intervention: Sulphasalazine treatment
Number of subjects: 32
Study: 8944992

Group type: EXPERIMENTAL
Intervention: Selective cerebral perfusion (SCP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard hypothermic cardiopulmonary bypass (Control)
Number of subjects: 20
Study: 1901686

Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanate suspension (Spektramox) for 7 days
Number of subjects: 102

Group type: COMPARATOR
Intervention: Amoxycillin suspension (Imacillin) for 10 days
Number of subjects: 102
Study: 6846478

Group type: EXPERIMENTAL
Intervention: Wrist immobilization by a commercially available splint
Number of subjects: 18

Group type: COMPARATOR
Intervention: Wrist free (control condition)
Number of subjects: 18